Actively Recruiting
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
Led by University Health Network, Toronto · Updated on 2026-02-12
30
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying advanced prostate cancer using two types of PET imaging: Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose (FDG) PET scans. The goal is to learn about tumor biology at different disease stages and during treatment, which may help guide future treatment choices and monitor how well treatments work. This study is interventional and sponsored by the University Health Network in Toronto. Participants with advanced prostate cancer will undergo PSMA and FDG PET scans before starting their standard care treatment and again during treatment. The scans use specialized radiotracers including Ga 68 PSMA-11 and 18F-DCFPyL for PSMA imaging and FDG for glucose metabolism imaging. The imaging will help assess tumor activity and changes over time. The study includes monitoring at multiple time points. During the study, participants will receive PET imaging exams and continue their usual care under oncology or urology doctors. Researchers will measure the proportion of patients with high volume metastatic castration-sensitive prostate cancer (mCSPC) showing PSMA active disease over five years. They will also evaluate the presence of discordant lesions between PSMA and FDG imaging. Participants will be monitored for safety and imaging results throughout the study period, which lasts at least five years.
CONDITIONS
Brief Title
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male, age 18 years or older
- Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
- Poor risk patients with metastatic castration-sensitive prostate cancer (mCSPC) at enrollment
- De novo or recurrent high volume mCSPC as per conventional imaging before starting ADT and ARPI
- High or low volume mCSPC with PSA level ≤4.0 after 6-8 months of starting ADT
- Willing to undergo study PET scans and remain under care of oncology or urology physician at Princess Margaret Cancer Center
- No prior PSMA or FDG PET imaging within 60 days at each study time point
- Patients enrolled in other clinical trials are eligible if they meet all other criteria
You will not qualify if you...
- Participation in a randomized-controlled trial with unknown systemic therapy allocation
- Inability to undergo or complete PSMA PET and FDG PET imaging exams
- Unable to provide written consent personally or by legal representative
- Conditions impairing ability to comply with study procedures or follow-up, as judged by physician
- Significant uncontrolled health issues affecting safety or imaging interpretation
- Another active malignancy
- Patient on dialysis
- Use of another radioisotope or investigational systemic agent within 5 half-lives before PET imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week
Participants undergo PSMA and FDG PET imaging before starting their standard of care treatment.
1 to 2 imaging visits
Duration - Up to 5 years
Participants are monitored with follow-up PSMA and FDG PET imaging during treatment and over time to assess disease status.
Periodic imaging visits depending on treatment schedule
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
D
Di (Maria) Jiang, M.D.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here